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Introduction
Nontraumatic terminal ileal perforation is a common cause of 
obscure peritonitis, and since the clinical features are similar 
to any other acute abdominal condition, patients are often 
misdiagnosed, resulting in delayed surgical intervention. Apart from 
intestinal tuberculosis, other common causes of ileal perforation 
include typhoid fever, non-specific inflammation, obstruction (e.g. 
Crohn’s disease) and radiation enteritis.1 Intestinal tuberculosis or 
tuberculosis enteritis commonly affects the ileocecal region, possibly 
because of the increased physiological stasis, abundant lymphoid 
tissue and high absorptive capacity.2 Tuberculosis enteritis may lead 
to perforation of the terminal ileum in 1-15% of cases, which usually 
occurs as a blowout of the small bowel secondary to distension 
caused by distal strictures or adhesions.2,3 Presenting symptoms 
include severe abdominal pain (100%), fever (57%), vomiting (42%), 
constipation (58%), dehydration (71%), tenderness (86%), distension 
(68%) and rigidity (32%).2 The treatment for tubercular peritonitis is 
the same as that for peritonitis due to other causes, and involves 
resuscitation, nasogastric aspiration, intravenous fluids, antibiotics 
and surgery, often necessitating the formation of an ileostomy.2,4 
Two important postoperative complications directly impacted on the 
patient’s nutritional care plan in this given case report. The one was 
a high-output ileostomy and the other, Guillain-Barré syndrome. 
High-output ileostomy
Patients often develop a high-output ileostomy (> 2 000 ml/day)5 
after stoma formation following bowel surgery.5,6 Although an early 
high-output ileostomy often resolves spontaneously, some patients 
require ongoing medical treatment in the form of anti-diarrhoeal 
drugs, octreotide and proton-pump inhibitors.5,6 Patients with 
a persistent high-output stoma are at risk of significant fluid and 
electrolyte imbalances, as well as protein energy malnutrition due to 
insufficient nutrient absorption.5 
Guillain-Barré syndrome 
Guillain-Barré syndrome is usually an acute-onset, monophasic, 
immune-mediated disorder of the peripheral nervous system, 
characterised by symmetric muscle weakness, loss of sensation 
and the loss of deep tendon reflexes.7,8 Guillain-Barré syndrome 
is often preceded by an infection in the upper respiratory tract or 
gastrointestinal tract. Organisms that are usually implicated in the 
development of Guillain-Barré syndrome include Campylobacter 
jejuni, cytomegalovirus, Epstein-Barr virus, Mycoplasma pneumonia 
and Haemophilus influenzae.8-10 Other factors associated with the 
development of Guillain-Barré syndrome include the stress of surgery, 
immunisation and parturition.10 Both intravenous immunoglobulin 
and plasma exchange are effective in the treatment of Guillain-Barré 
syndrome.11 The goals of nutrition therapy for patients with Guillain-
Barré syndrome are the same as those for any other critically ill 
patient. Since weaning from the ventilator is often difficult, optimal 
nutrition therapy plays a very important role; firstly, since nutritional 
repletion is essential to build up the musculature, and secondly, to 
avoid overfeeding, as this may lead to an increased ventilator load.12 
However, despite the delivery of optimal nutrition therapy, Guillain-
Barré syndrome patients often lose a significant amount of weight due 
to various factors, including stress-induced catabolism, prolonged 
bed rest, as well as certain medications, e.g. corticosteroids.12 
Furthermore, Guillain-Barré syndrome patients often present with 
oropharyngeal weakness and subsequent swallowing dysfunction, 
as well as autonomic nervous system dysfunction, which, in turn, 
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may lead to gastrointestinal dysmotility, and in severe cases, ileus.7,11 
Dysmotility is frequently managed with nasogastric suctioning, the 
administration of erythromycin or neostigmine, and in severe cases, 
the suspension of enteral nutrition.7 
Case study
A 51-year old female (recumbent length of 172 cm, an estimated 
weight of 50 kg and a usual weight of 56 kg ± 1 month prior as 
reported by the family) was admitted to the medical ward of a 
Johannesburg Hospital on Thursday, 3 July 2014, with severe 
abdominal pain, nausea and vomiting. The symptoms had begun one 
week previously, but increased in severity over the last three days. 
The patient reported the last instances of flatulence and defecation 
being two days prior to hospitalisation. On examination, she was 
febrile, appeared dehydrated and showed signs of peritonitis. 
A laboratory evaluation revealed a positive human immunodeficiency 
virus (HIV) status (CD4 count of 132 cells/mm3), leucocytosis (13.9 
x 109/l), hyponatraemia (128 mmol/l), and pre-renal failure (urea 
17.1 mmol/l and creatinine 203 µmol/l), which responded to 
adequate fluid resuscitation in the ward. An X-ray examination 
of the chest showed free air under the diaphragm, followed by 
abdominal sonography, suggesting features of a perforated bowel. 
There was free fluid in the peritoneal cavity, with multiple, dilated, 
fluid-filled loops in the small bowel. Nasogastric decompression was 
performed, and the patient was prepared for surgical exploration. A 
laparotomy, performed on Saturday, 5 July, with a midline incision, 
revealed purulent peritoneal fluid, mainly in the pelvis, as well as 
a perforated gangrenous loop of terminal ileum 50 cm from the 
ileocaecal valve, with a distended proximal bowel. Approximately 
15 cm of necrotic small bowel was resected, and a double-barrel 
ileostomy brought out. This was followed by a thorough peritoneal 
washout and abdominal closure. A provisional diagnosis of a small 
bowel performation secondary to ileal tuberculosis was made, and 
later confirmed by histopathology, and the patient was transferred to 
the intensive care unit (ICU) for further medical management.
On arrival in the ICU, the patient was haemodynamically stable, 
with a mean arterial pressure of 73 mmHg, and was placed on a 
low dose of inotropic support, i.e. adrenaline at 0.04 µg/kg/minute. 
A laboratory evaluation revealed an elevated C-reactive protein (CRP) 
of 134 mg/l, leucocytosis of 13.1 x 109/l and hypoalbuminaemia of 
22 g/l. On physical examination, she was febrile (38.8°C). Her pulse 
rate was 115 beats/minute and her respiratory rate 24 breaths/
minute (managed on 40% facial mask oxygen). The patient’s blood 
glucose levels ranged from 8-10 mmol/l. 
She was immediately placed on the following therapy:
•	 Empiric antitubercular treatment of rifafour 4 tablets per os, daily, 
and pyridoxine 25 mg per os, daily.
•	 A broad-spectrum antibiotic, i.e. tazobactam 18 g, over 24 hours, 
intravenously, for seven days.
•	 An antifungal medicine, i.e. fluconazole 400 mg, intravenously, 
daily.
•	 An analgesic, i.e. morphine 1-2 mg, intravenously, four hourly.
•	 An antithrombotic agent, i.e. clexane 40 mg, subcutaneously, 
daily.
•	 An ulcer prophylactic, i.e. ulsanic 1 g per os, six hourly. 
The patient was kept nil per os and received intravenous fluid 
therapy in the form of Balsol®. 
By the next morning (day 2 in the ICU), the patient’s blood pressure 
began to improve and inotropic support was discontinued. She was 
fully awake, responsive and maintained adequate oxygen saturation 
via a facial mask, i.e. fraction of inspired oxygen 2 (FiO
2) of 40%. 
However, she presented with progressive weakness, and after a 
neurological review, was diagnosed with postoperative Guillain-Barré 
syndrome. The patient was subsequently placed on a six-day course 
of immunoglobulin therapy, i.e. Polygam® 24 g, intravenously, daily, 
which contains ± 33.6 g sucrose as a stabiliser, and received an 
intravenous calcium replacement, i.e. calcium gluconate 10 ml 10%, 
over 10 minutes, for severe hypocalcaemia, with corrected calcium 
of 1.89 mmol/l. The nasogastric tube, still on free drainage, drained 
300 ml over 24 hours. On physical examination, the abdomen was 
soft and tender, with positive bowel sounds. The attending physician 
prescribed a mixed-fluid diet.
By day 3 in the ICU (Monday morning, 7 July 2014), the patient’s oral 
intake remained poor. She had now developed a septic abdominal 
wound, further complicated by a high-output ileostomy, i.e. three 
litres over the past 24 hours. On physical examination, her abdomen 
appeared to be tense and slightly distended. A laboratory analysis 
revealed severe hypoalbuminaemia, as well as hypokalaemia, 
hypocalcaemia and hypophosphataemia. Stool cultures were sent 
for Clostridium difficile testing. The result was negative, and the 
patient was referred to the dietitian for nutritional intervention. 
Question 1: What are your decisions with regard to the 
patient’s nutritional requirements on day 3 in the intensive 
care unit? What nutritional intervention do you suggest?
Parenteral nutrition (PN) was recommended, based on the following 
nutrition-related problems:
•	 Grade II protein-energy malnutrition (PEM): An estimated body 
mass index (BMI) of 16.9 kg/m2, with significant weight loss 
(± 10.7% over one month) and little to no nutritional intake for 
> 5 days.
•	 Increased nutritional requirements: A hypermetabolic and 
hypercatabolic state, relating to abdominal sepsis, Guillain-Barré 
syndrome, HIV/acquired immune deficiency syndrome (AIDS) and 
abdominal tuberculosis.
•	 Increased nutrient losses and severe malabsorption: High-output 
ileostomy.
•	 Other: Post major gastrointestinal surgery, severe hypoalbumi-
naemia and abdominal distension.
Since there was no absolute contraindication to enteral nutrition, 
trophic feeding at 10-20 ml/hour was recommended in order to 
maintain gut trophicity. An isotonic semi-elemental enteral nutrition 
formula was chosen because of the abdominal distension, severe 
hypoalbuminaemia and significant nutrient malabsorption. 
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A total energy target of 25-30 kcal/kg actual body weight and 1.3-1.5g 
protein/kg ideal body weight was recommended. Owing to the risk of 
refeeding syndrome, based on PEM, low to no nutritional intake for 
> 5 days, hypokalaemia, hypophosphataemia and hypomagnesae-
mia, a decision was made to gradually initiate and advance the 
feeding in conjunction with a daily electrolyte replacement and 
micronutrient supplementation, and thiamine, in particular. The 
energy contribution from Polygam®, in the form of sucrose, was 
considered to be part of the total energy intake.
Rationale
Although the indications for PN remain largely unchanged, and two 
recent review articles13,14 have suggested the need for PN in the case 
of significant nutrient malabsorption, e.g. high-output enterostomies 
of > 2 litres/24 hours, current clinical practice guidelines on its 
optimal timing are contradictory.13 According to the European Society 
for Clinical Nutrition and Metabolism (ESPEN), patients who are not 
expected to be on normal nutritional intake within three days of the 
onset of disease should receive PN within 24-48 hours if enteral 
nutrition is contraindicated, or if it cannot be tolerated.15 Despite 
a more delayed approach of 7-10 days, as recommended by the 
American Society for Parenteral and Enteral Nutrition (ASPEN), the 
general consensus remains that PN should be initiated as soon 
as possible if there is evidence of PEM on admission and enteral 
nutrition is not feasible.13,15,16 Although serum secretory protein, e.g. 
serum albumin, is not a valid marker of nutritional status in critical 
illness, it can be used with other parameters, e.g. CRP, as a proxy 
indicator of inflammatory status, and hence disease severity, which, 
in turn, is a potent contributor to disease-related malnutrition.17,18 
Therefore, inflammatory status and disease severity can be used 
together with nutritional status and nutrient intake to identify 
patients at high nutritional risk who are likely to benefit from early 
goal-directed feeding.19 
A small amount of enteral nutrition, e.g. 250 ml/day, typically 
administered as a trophic feed at 10-20 ml/hour, is possible in 
most patients requiring PN unless enteral nutrition is an absolute 
contraindication, e.g. bowel left in discontinuity after damage 
control laparotomy, and offers additional non-nutritional benefits, 
such as being able to maintain gut integrity, attenuate oxidative 
stress, promote insulin sensitivity, increase brush-border enzymes, 
restore commensal bacteria, and stimulate bowel motility and 
immunoglobulin A secretion.13,14,19 This may be of particular benefit 
to patients with Guillain-Barré syndrome since they often present 
with gastrointestinal dysmotility, resulting from autonomic nervous 
system dysfunction, further worsened by long-term immobilisation 
and the administration of opiates for pain control.20,21 
Severely malnourished patients on PN and/or those at risk of 
refeeding syndrome should initially receive 10 kcal/kg actual 
body weight/day, progressively increasing the target to reach 
25-30 kcal/kg actual body weight/day over 3-4 days.14,15 Owing to 
the potential risk of overfeeding, especially in patients receiving a 
combination of PN and enteral nutrition, daily monitoring of actual 
energy intake, inclusive of non-nutritional energy sources, e.g. 
propofol, Polygam® and intravenous dextrose, is clearly warranted. 
Furthermore, PN should be gradually weaned over time when enteral 
nutrition reaches the energy target.13,14,22-24
Apart from achieving an adequate energy intake, optimal protein 
provision is as important, and may offer a significant mortality 
benefit.25,26 ESPEN and ASPEN recommend a daily protein intake 
in the range of 1.3-1.5 g/kg and 1.2-2.0 g/kg, respectively.15,16 ICU 
patients with a daily protein intake of 1.5 g/kg had a significantly 
lower mortality compared to those receiving only 0.8 g/kg or 
1.1 g/kg, independently of energy intake, in an observational study by 
Allingstrup et al.25 According to Puthucheary et al,27 muscle wasting 
occurs early and rapidly during the first week of critical illness. 
Therefore, a high protein intake of 1.5 g/kg/day, combined with early 
mobilisation, may help to overcome anabolic resistance, especially 
in the acute phase of illness.23 Appropriately designed randomised 
controlled trials are needed to confirm the optimal macronutrient 
distribution in the different phases of critical illness.22,23 
An adequate micronutrient supply is another important component 
of optimal nutrition therapy. Henceforth, ESPEN recommends that 
all PN bags should include a daily dose of multivitamins and trace 
elements (grade C).15 Critically ill patients, in particular, are at risk 
of developing micronutrient deficiencies. This is partly owing to 
increased requirements, but is also often as a result of pre-existing 
deficiencies, increased losses (e.g. high-output enterostomy), drug-
nutrient interactions (e.g. vitamin B
6 in antitubercular treatment) 
and/or an inadequate intake.28,29 Therefore, micronutrients should 
be included in the nutritional care plan, especially since they play 
an important role in substrate metabolism, cellular immunity, 
wound healing and antioxidant defences. The latter is particularly 
challenging in the critically ill patient.15, 28-30 Furthermore, daily 
thiamine supplementation, together with the correction of fluid 
and electrolyte imbalances, plays an important role in preventing 
refeeding syndrome.24,31 Therefore, in order to minimise fluid and 
electrolyte losses via the ileostomy, preference should be given to an 
isotonic enteral nutrition formula of osmolality near 300 mOsmol/kg, 
with a sodium concentration near 100 mmol/l, and preferably semi-
elemental to facilitate nutrient absorption.32,33 
Question 2: What are your decisions regarding glutamine in the 
current setting?
Given the fact that this was a malnourished patient, post major 
gastrointestinal tract surgery, with no signs of multi-organ failure, 
shock or renal and liver dysfunction, a decision was taken to add 
intravenous glutamine supplementation to the prescribed all-in-one 
PN regimen, in order to provide 0.2-0.4 g/kg/day of L-Glutamine. 
Furthermore, a decision was taken to avoid enteral glutamine 
supplementation.
Rationale
According to the ESPEN guidelines on PN, the amino acid 
solution should contain 0.2-0.4 g/kg/day of L-Glutamine, i.e. 0.3- 
0.6 g/kg/day of alanyl-glutamine dipeptide.15 Early high-dose 
glutamine supplementation given separate from nutrition therapy 
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offered no benefit, and may have been associated with increased 
mortality in critically ill patients with multi-organ failure in the recent 
REducing Deaths due to OXidative Stress (REDOXs) study by Heyland 
et al.34 Therefore, until further safety and efficacy data are available 
from adequately powered randomised controlled trials, glutamine 
administration should be avoided in critically ill patients with multi-
organ failure, and particularly in those with concomitant renal 
dysfunction.35,36 However, a large body of evidence still remains that 
suggests the beneficial treatment effect of intravenous glutamine 
supplementation at 0.35 g/kg/day in critically ill patients not 
experiencing multi-organ failure, and receiving PN.37  Furthermore, 
based on weak data from small studies, enteral glutamine 
supplementation of 0.3-0.5 g/kg/day should only be considered in 
burn or trauma patients, and not in general critically ill patients.37
Four days later (day 7 in the ICU), inotropic and vasopressor support, 
in the form of adrenaline, was restarted for new-onset hypotension, 
and the patient required intubation and mechanical ventilation for 
worsening arterial hypoxaemia [partial pressure of O
2 in arterial 
blood (PaO2)/FiO2 < 300 mmHg]. In addition, she presented with 
an elevated urea and creatinine, metabolic acidosis and a tapering 
urine output. Intravenous fluid therapy, in the form of 5% dextrose 
water with added sodium bicarbonate, prescribed at 60 ml/hour, 
was administered to improve renal perfusion and treat metabolic 
acidosis. Furthermore, she was placed on a continuous insulin 
infusion for worsening blood glucose control, i.e. 10-12 mmol/l on 
average. Ileostomy output remained high at 2.1 l/day. The patient 
remained C. difficile-negative. 
Question 3: Would you make any changes, or additions, to the 
patient’s current feeding prescription, in view of the clinical 
picture on intensive care unit day 7?
A total daily energy intake of 20-25 kcal/kg was recommended 
owing to the new bout of stress being experienced, i.e. severe 
sepsis with hypoperfusion, and subsequent multi-organ failure 
[acute lung injury, acute kidney injury (AKI) and hypotension 
requiring vasoactive support]. In an attempt to reduce the risk of 
overfeeding and to improve blood glucose control, the additional 
energy delivered via the 5% dextrose water and Polygam® 
infusion was taken into account. The protein target was reduced to 
1.2 g/kg/day since an overzealous protein delivery can worsen 
azotaemia in AKI patients not on renal replacement therapy (RRT). 
However, due to the patient’s hypermetabolic and hypercatabolic 
state, i.e. severe sepsis, metabolic acidosis, HIV/AIDS and 
tuberculosis, a protein restriction of less than 1 g/kg/day was 
strongly discouraged, as this would have aggravated the loss of 
lean body mass. An upper limit for vitamin C intake was set at 100 
mg/day to prevent the development of secondary oxalosis. Owing 
to a persistently high ileostomy output, a decision was taken to 
continue PN together with a trophic enteral feed. An electrolyte-
free PN regimen and a low electrolyte enteral nutrition formula was 
recommended, in order to further avoid the worsening of electrolyte 
derangement. 
Rationale
ICU patients exhibit an increasing spectrum of intertwined 
pathophysiological processes, making an individualised approach to 
nutrition therapy essential. In addition, a patient’s nutritional needs 
will constantly change during his or her ICU stay, depending on the 
stage of critical illness, i.e. acute versus chronic or recovery phase, 
and depending on the treatment modalities, e.g. daily RRT and 
surgery.22 
Vasopressors and inotropes are routinely given to hemodynamically 
unstable patients to maintain adequate blood pressure and cardiac 
output.38 Adrenaline acts as an inotrope at low doses by increasing 
cardiac contractility, and hence cardiac output. However, adrenaline 
acts as an inotrope and vasopressor at high doses. Vasopressors 
increase blood pressure by elevating the sensitivity of the gut to 
vasoconstriction, thereby increasing the risk of ischaemia and 
associated mortality.38 However, the general consensus remains that 
vasopressors are not a contraindication to carefully monitored early 
enteral nutriton.38,39 Previous studies have shown that early enteral 
nutrition in patients treated with vasopressors may improve gut 
perfusion and preserve bowel absorptive capacity.39 Furthermore, 
Khalid, Doshi and DiGiovine40 found that patients treated with 
vasopressors and fed within 48 hours of ICU admission had a lower 
hospital mortality of 34% vs. 44% (p-value < 0.001), and that the 
most severely ill patients and those receiving multiple vasopressors 
benefited the most from early enteral nutrition.
The ESPEN guidelines recommend a daily total energy intake of 20-
25 kcal/kg body weight in the initial acute phase of illness, which 
should then be increased to 25-30 kcal/kg body weight once the 
patient progresses to the chronic or the recovery phase of illness.22 
This is in line with the recently published Kidney Disease: Improving 
Global Outcomes (KDIGO) recommendations of 20-30 kcal/kg 
body weight in patients with any stage of AKI,41 as well as the 
recently published recommendations by McCarthy and Phipps42 
suggesting an energy intake of 20-30 kcal/kg body weight, with up 
to 35 kcal/kg body weight/day, if undergoing continuous RRT. 
The protein target for patients with AKI should be calculated 
based on the underlying condition and treatment modality, i.e. no 
RRT versus intermittent RRT versus continuous RRT.42 Restricting 
protein intake with the aim of preventing or delaying the need for 
RRT should be avoided (grade 2D).41 The hypercatabolic patient, e.g. 
AKI secondary to severe sepsis, is more susceptible to malnutrition 
and increased protein losses owing to metabolic acidosis, uraemia, 
fluid and electrolyte imbalances, as well as physiological stress from 
infection, inflammation and tissue destruction.42 Therefore, restricting 
protein intake to less than 1 g/kg/day may aggravate malnutrition in 
hypercatabolic patients. Lastly, vitamin C intake should be restricted 
to less than 100 mg/day in AKI patients not requiring continuous 
RRT since it may precipitate secondary oxalosis, leading to delayed 
recovery of renal function.42 
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Question 4: On day 7, the attending physician asks whether 
or not intravenous glutamine supplementation should be 
continued (or added if not yet prescribed). What do you 
suggest and why?
Glutamine supplementation (intravenous and enteral) should be 
discontinued on the basis of multi-organ failure, i.e. AKI, acute 
lung injury (PaO
2/FiO2 < 300 mmHg), and hypotension requiring 
vasoactive support (see the rationale provided for question 3).  
The patient was anuric the next day, i.e. day 8 in the ICU, and 
required daily RRT in the form of sustained low-efficiency dialysis 
(SLED). Intravenous fluid therapy was stopped, and fluid intake 
derived from the feeding prescription alone. The patient’s blood 
culture grew vancomycin-resistant Enterococcus faeciam and the 
linezolid antibiotic therapy dose and frequency was escalated. The 
ileostomy output reduced to 600-800 ml/day. 
Question 5: Will the patient’s nutritional requirements have 
altered since the previous day (day 7)? If yes, explain why, and 
how you would adjust her feeding prescription?
Yes. The protein and micronutrient intake was increased to 
compensate for the increased losses of amino acids, peptides, 
water-soluble vitamins and trace elements via the dialysate. An 
energy- and protein-dense feed was recommended in order to 
achieve an adequate nutrient intake within a restricted fluid volume. 
Rationale
Critically ill patients with AKI often require RRT in the form of highly 
efficient modalities, such as SLED or continuous haemofiltration or 
dialysis, with potentially relevant effects on the nutrient balance.43 
A protein catabolic rate in the range of 1.4-1.75 g/kg body weight/
day has been reported, especially in those treated with continuous 
RRT.43-45 Furthermore, approximately 0.2 g amino acid is lost per 
litre of filtrate, amounting to a total daily loss of 10-15 g amino 
acid. In addition, 5-10 g of protein are lost per day, depending on 
the type of therapy and dialyzer membrane used.41 A daily protein 
target of at least 1.5 g/kg body weight(1.5-2 g/kg body weight) is 
recommended in patients on intermittent dialysis, e.g. SLED, in order 
to achieve a less negative or nearly positive nitrogen balance and 
to offset losses via the dialysate.42-45 Although the optimal dose of 
micronutrient supplementation in AKI is unknown, water-soluble 
vitamins, e.g. thiamine and vitamin C, as well as trace elements, 
especially copper and selenium, are easily removed by RRT. Hence, 
daily supplementation with a standard dose of multi-trace element 
preparations is recommended.42-45 
The patient markedly improved over the next five days. The 
laboratory and blood gas analysis showed a gradual decline in 
septic markers, as well as an overall improvement in acid base 
status and renal function. By day 14, RRT was discontinued, and 
the patient no longer required inotropic and vasopressor support. 
Furthermore, after several trials of spontaneous breathing, the 
patient was successfully weaned from the ventilator. However, she 
remained immensely weak, and received daily physiotherapy to 
ensure adequate mobilisation. Her ileostomy output reduced to 300-
400 ml daily. She was transferred to a high care unit and referred to 
the dietitian for nutritional rehabilitation.   
Question 6: What would you suggest to ensure optimal 
nutritional and functional recovery?
This was the opinion of the audience, hence change sentence to: 
“A rehabilitation plan with the aid of a physiotherapist and dietitian 
should be implemented in an attempt to regain lean body mass and 
functional capacity. This plan should consist of daily mobilisation, 
combined with optimal nutrient delivery, i.e. energy 35-45 kcal/kg 
body weight and protein 1.5-2.5 g/kg body weight. Early on, the 
patient’s swallowing ability and risk of aspiration should be assessed 
by a speech therapist, followed by the initiation of oral feeds, with 
the necessary consistency changes. Energy- and protein-dense 
oral nutrition supplements aid in achieving an adequate energy 
and protein intake, thereby facilitating weight gain. In the case of 
persistently inadequate oral feeds, enteral tube feeding should be 
switched over to intermittent feeding at night, rather than during 
the day, to allow the patient to freely partake in physiotherapy 
sessions during the day. Importantly, enteral nutrition should only 
be discontinued once 60-80% of the patient’s nutrient targets 
have been met via the oral route alone. Additional micronutrient 
supplementation should also be considered, especially in the case 
of an established deficiency. Furthermore, the patient’s ileostomy 
output must be monitored for possible diarrhoea or constipation, and 
the nutrition care plan adjusted accordingly.   
Rationale
Optimal nutrition therapy continues to play a crucial role during 
the chronic and recovery phase of critical illness. Guillain-Barré 
syndrome, in particular, is associated with prolonged weakness.46 
Approximately 40% of patients diagnosed with Guillain-Barré 
syndrome need inpatient rehabilitation.21 As mentioned previously, 
Guillain-Barré syndrome patients often lose a significant amount 
of weight, and this, together with prolonged immobilisation, makes 
such patients highly susceptible to the development of bed sores.12,46 
Furthermore, Guillain-Barré syndrome patients are at risk of muscle 
shortening and joint contractures.46 Providing optimal nutrition 
therapy, in combination with daily physiotherapy, aids in rebuilding 
lean body mass, ultimately improving physical function and quality 
of life. According to Thibault and Pichard,47 hospitalised long-stay 
patients in the post-acute phase of illness who are malnourished 
should receive 30-35 kcal/kg body weight. Higher energy and 
protein targets of 40-45 kcal/kg body weight and 2-2.5 g protein/
kg body weight have previously been suggested in patients with 
Guillain-Barré syndrome in order to reduce muscle wasting.20 Since 
Guillain-Barré syndrome patients often present with dysphagia 
secondary to oropharyngeal weakness and prolonged ventilation,20 
consistency changes may improve swallowing and reduce the risk of 
aspiration. Furthermore, Guillain-Barré syndrome patients who are 
in the recovery phase often present with constipation, mostly as a 
result of long-term immobilisation and the administration of opiates 
for pain control.20,21 Therefore, regular monitoring of a patient’s 
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ileostomy output is important. 
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